Home › Psoriasis › NCT04347473
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RecruitingPhase 4
A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by * BSA 10% * PGA ≥3 * PASI ≥12 3. Must be a candidate for phototherapy and/or systemic therapy 4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. Exclusion Criteria: 1. Non-plaque forms of psoriasis 2. Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating 3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial. 4. Active or untreated latent tuberculosis (TB)
About the study
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
What is being tested
- Ilumya Injectable Product (drug)
Sponsor: Psoriasis Treatment Center of Central New Jersey · Participants: 25 · Started: Apr 6, 2020
Contact the study team
- Jerry Bagel, MD · Phone: 6094434500
- Elise Nelson · Phone: 6094434500
Official record on ClinicalTrials.gov — NCT04347473
Locations in the U.S.
| New Jersey | Psoriasis Treatment Center of Central New Jersey, East Windsor |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.